Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on May 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). Item 7.01 provides no substantive investor disclosure in the supplied text.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Item 7.01 provides no substantive investor disclosure in the supplied text
- The filing’s information is excluded from incorporation by reference into future Securities Act or Exchange Act filings
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.